
As healthcare budgets become increasingly stretched by the demands of coping with long-term illnesses, interest is growing in the manufacturing …

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a maintenance treatment for asthma in …

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed through symptoms, lung function and …
1 Chronic obstructive pulmonary disease is a group of progressive lung conditions, principally emphysema and chronic bronchitis, that restrict airflow …

Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and putting the patient at the …
Launched in February 2026 by PMGroup Worldwide Ltd and Visions4Health, the Excellence in Healthcare Partnerships (EHP) Awards recognise outstanding collaborations …

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a maintenance treatment for asthma in …

AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation …

By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, access, and willingness to enrol. …

Advances in computed tomography (CT) technology are helping to reshape the diagnosis and management of chronic respiratory disease, with new …

Andera Partners, a private equity firm, has announced its leadership of a $67m series A financing round in Spiro Medical, …

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …

Digital medicine company electronRx, based in Cambridge, UK, has announced the upcoming launch of pDx, a mobile app designed to …

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …

GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …